These findings provide further support for the cardiometabolic benefits of SGLT2 inhibitors in HF management, though longer‐term studies are needed to clarify the clinical significance of EAT regression and its impact on HF outcomes. The gene discussed is SLC5A2; the disease is hydrops fetalis.